Andrew S. Fein

Flex Pharma Inc (NASDAQ: FLKS) provided regulatory and clinical updates for FLX-787, the company’s pharmaceutical transient receptor potential [TRP] ion channel agonist. Commenting on Flex Pharma’s Q3 results, H.C. Wainwright’s Andrew S. Fein said in a report that any visibility...

Kamada Ltd (NASDAQ: KMDA) reported positive topline results from its Phase 2 biomarker study of inhaled alpha-1 [AAT-IH] for the treatment of alpha-1 antitrypsin deficiency [AATD]. H.C. Wainwright’s Andrew S. Fein maintained a Buy rating on the company, with a price target of $10. The...

H.C. Wainwright’s Andrew S. Fein believes the bull thesis for Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) can no longer by supported only by Orkambi, and the company needs to focus on developing and diversifying its pipeline. Fein reiterated a Buy rating on the company, with a $155...

HC Wainwright’s Andrew S. Fein initiated coverage of Proteostasis Therapeutics Inc (NASDAQ: PTI) with a Buy rating and a price target of $15. The company develops disease-modifying therapeutics for diseases related to protein processing. At a time when combination-driven treatments are...

H.C. Wainwright's Andrew S. Fein reiterated a Buy rating on Amarin Corporation plc (ADR) (NASDAQ: AMRN), with a price target of $10. The DMC decision is expected July–August 2016, and Fein believes that the study is likely to be recommended to be continued as planned. However, management...

Last week, H.C. Wainwright’s Andrew S. Fein attended an NTM-focused workshop at the meeting of the European Respiratory Society (ERS) in Amsterdam. After the event, the firm reiterated a Buy rating on Insmed Incorporated (NASDAQ: INSM), and raised its price target to $35.00. Shares...

H.C. Wainwright commented on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Wednesday following the FDA AdCom endorsement to approve Orkambi as the stock surged over 5 percent in pre-market trading. Analyst Andrew S. Fein believed that since the Phase 3 win and going into the AdCom, “...

OvaScience Inc (NASDAQ: OVAS) extended its losses Monday on worries over testing results of its fertility treatment. Shares fell 5.3 percent recently to $41.16. The shares are off more than 12 percent in the past five trading days. OvaScience last week posted results of a small study revealing nine...

In a report published Wednesday, H.C. Wainwright analyst Andrew S. Fein reiterated a Neutral rating and $85.00 price target on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). In the report, H.C. Wainwright noted, “During the last year, we had alerted investors on the pending multiplication of...

In a report published Monday, H.C. Wainwright & Co. analyst Andrew S. Fein initiated coverage on Seattle Genetics (NASDAQ: SGEN) with a Buy rating and $65.00 price target. In the report, H.C. Wainwright & Co. noted, “We believe that Adcetris, anti-CD30-targeted antibody drug conjugate (ADC...

In a report published Monday, H.C. Wainwright & Co. analyst Andrew S. Fein initiated coverage on BioCryst Pharmaceuticals (NASDAQ: BCRX) with a Buy rating and $21.00 price target. In the report, H.C. Wainwright & Co. noted, “Biocryst's BCX4161 (a potent oral kallikrein inhibitor) recently...